Kelly D Getz1,2, Lillian Sung3, Todd A Alonzo4, Kasey J Leger5, Robert B Gerbing6, Jessica A Pollard7, Todd Cooper5, E Anders Kolb8, Alan S Gamis9, Bonnie Ky2, Richard Aplenc1,2. 1. Children's Hospital of Philadelphia, Philadelphia, PA. 2. University of Pennsylvania, Philadelphia, PA. 3. The Hospital for Sick Children, Toronto, Ontario, Canada. 4. University of Southern California, Los Angeles, CA. 5. Seattle Children's Hospital, Seattle, WA. 6. Children's Oncology Group, Monrovia, CA. 7. Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. 8. Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE. 9. Children's Mercy Hospital and Clinics, Kansas City, MO.
Abstract
PURPOSE: To determine whether dexrazoxane provides effective cardioprotection during frontline treatment of pediatric acute myeloid leukemia (AML) without increasing relapse risk or noncardiac toxicities of the chemotherapy regimens. PATIENTS AND METHODS: This was a multicenter study of all pediatric patients with AML without high allelic ratio FLT3/ITD treated in the Children's Oncology Group trial AAML1031 between 2011 and 2016. Median follow-up was 3.5 years. Dexrazoxane was administered at the discretion of treating physicians and documented at each course. Ejection fraction (EF) and shortening fraction (SF) were recorded after each course and at regular intervals in follow-up. Per protocol, anthracyclines were to be withheld if there was evidence of left ventricular systolic dysfunction (LVSD) defined as SF < 28% or EF < 55%. Occurrence of LVSD, trends in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and treatment-related mortality (TRM) were compared by dexrazoxane exposure. RESULTS: A total of 1,014 patients were included in the analyses; 96 were exposed to dexrazoxane at every anthracycline course, and 918 were never exposed. Distributions of sex, age, race, presenting WBC count, risk group, treatment arm, and compliance with cardiac monitoring were similar for dexrazoxane-exposed and -unexposed patients. Dexrazoxane-exposed patients had significantly smaller EF and SF declines than unexposed patients across courses and a lower risk for LVSD (26.5% v 42.2%; hazard ratio, 0.55; 95% CI, 0.36 to 0.86; P = .009). Dexrazoxane-exposed patients had similar 5-year EFS (49.0% v 45.1%; P = .534) and OS (65.0% v 61.9%; P = .613) to those unexposed; however, there was a suggestion of lower TRM with dexrazoxane (5.7% v 12.7%; P = .068). CONCLUSION: Dexrazoxane preserved cardiac function without compromising EFS and OS or increasing noncardiac toxicities. Dexrazoxane should be considered for cardioprotection during frontline treatment of pediatric AML.
PURPOSE: To determine whether dexrazoxane provides effective cardioprotection during frontline treatment of pediatric acute myeloid leukemia (AML) without increasing relapse risk or noncardiac toxicities of the chemotherapy regimens. PATIENTS AND METHODS: This was a multicenter study of all pediatric patients with AML without high allelic ratio FLT3/ITD treated in the Children's Oncology Group trial AAML1031 between 2011 and 2016. Median follow-up was 3.5 years. Dexrazoxane was administered at the discretion of treating physicians and documented at each course. Ejection fraction (EF) and shortening fraction (SF) were recorded after each course and at regular intervals in follow-up. Per protocol, anthracyclines were to be withheld if there was evidence of left ventricular systolic dysfunction (LVSD) defined as SF < 28% or EF < 55%. Occurrence of LVSD, trends in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and treatment-related mortality (TRM) were compared by dexrazoxane exposure. RESULTS: A total of 1,014 patients were included in the analyses; 96 were exposed to dexrazoxane at every anthracycline course, and 918 were never exposed. Distributions of sex, age, race, presenting WBC count, risk group, treatment arm, and compliance with cardiac monitoring were similar for dexrazoxane-exposed and -unexposed patients. Dexrazoxane-exposed patients had significantly smaller EF and SF declines than unexposed patients across courses and a lower risk for LVSD (26.5% v 42.2%; hazard ratio, 0.55; 95% CI, 0.36 to 0.86; P = .009). Dexrazoxane-exposed patients had similar 5-year EFS (49.0% v 45.1%; P = .534) and OS (65.0% v 61.9%; P = .613) to those unexposed; however, there was a suggestion of lower TRM with dexrazoxane (5.7% v 12.7%; P = .068). CONCLUSION:Dexrazoxane preserved cardiac function without compromising EFS and OS or increasing noncardiac toxicities. Dexrazoxane should be considered for cardioprotection during frontline treatment of pediatric AML.
Authors: Cindy L Schwartz; Leonard H Wexler; Mark D Krailo; Lisa A Teot; Meenakshi Devidas; Laurel J Steinherz; Allen M Goorin; Mark C Gebhardt; John H Healey; Judith K Sato; Paul A Meyers; Holcombe E Grier; Mark L Bernstein; Steven E Lipshultz Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan Journal: Lancet Oncol Date: 2010-09-16 Impact factor: 41.316
Authors: Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Lillian Sung; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Samir B Kahwash; Amy Heerema-McKenney; Laura Winter; Kathleen Glick; Stella M Davies; Patti Byron; Franklin O Smith; Richard Aplenc Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Barbara L Asselin; Meenakshi Devidas; Lu Chen; Vivian I Franco; Jeanette Pullen; Michael J Borowitz; Robert E Hutchison; Yaddanapudi Ravindranath; Saro H Armenian; Bruce M Camitta; Steven E Lipshultz Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Alix E Seif; Dana M Walker; Yimei Li; Yuan-Shung V Huang; Marko Kavcic; Kari Torp; Rochelle Bagatell; Brian T Fisher; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2014-03-26 Impact factor: 3.167
Authors: Todd M Cooper; Michael J Absalon; Todd A Alonzo; Robert B Gerbing; Kasey J Leger; Betsy A Hirsch; Jessica Pollard; Bassem I Razzouk; Richard Aplenc; E Anders Kolb Journal: J Clin Oncol Date: 2020-05-13 Impact factor: 44.544
Authors: Eric J Chow; Richard Aplenc; Lynda M Vrooman; David R Doody; Yuan-Shung V Huang; Sanjeev Aggarwal; Saro H Armenian; K Scott Baker; Smita Bhatia; Louis S Constine; David R Freyer; Lisa M Kopp; Wendy M Leisenring; Barbara L Asselin; Cindy L Schwartz; Steven E Lipshultz Journal: Cancer Date: 2021-10-13 Impact factor: 6.860
Authors: Richard Aplenc; Soheil Meshinchi; Lillian Sung; Todd Alonzo; John Choi; Brian Fisher; Robert Gerbing; Betsy Hirsch; Terzah Horton; Samir Kahwash; John Levine; Michael Loken; Lisa Brodersen; Jessica Pollard; Susana Raimondi; Edward Anders Kolb; Alan Gamis Journal: Haematologica Date: 2020-02-06 Impact factor: 9.941
Authors: Haylie C Lawson; Margaret L Musser; Rebecca Regan; Antony S Moore; Ann Hohenhaus; Brian Flesner; Chad M Johannes Journal: J Vet Intern Med Date: 2021-11-25 Impact factor: 3.333
Authors: Neel S Bhatt; Malek J Baassiri; Wei Liu; Nickhill Bhakta; Wassim Chemaitilly; Matthew J Ehrhardt; Hiroto Inaba; Kevin Krull; Kirsten K Ness; Jeffrey E Rubnitz; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Leukemia Date: 2021-01-25 Impact factor: 11.528
Authors: Hugo R Martinez; Gary S Beasley; Jason F Goldberg; Mohammed Absi; Kaitlin A Ryan; Karine Guerrier; Vijaya M Joshi; Jason N Johnson; Cara E Morin; Caitlin Hurley; Ronald Ray Morrison; Parul Rai; Jane S Hankins; Michael W Bishop; Brandon M Triplett; Matthew J Ehrhardt; Ching-Hon Pui; Hiroto Inaba; Jeffrey A Towbin Journal: Children (Basel) Date: 2021-12-18